- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00228891
Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus
Effects of Pulsatile Insulin Delivery on Peripheral Diabetic Neuropathy
Study Overview
Status
Conditions
Detailed Description
Diabetic neuropathy (DN) is a progressive complication causing serious problems in 25%-40% of diabetic patients. Significant complications produce painful peripheral dysesthesias, loss of sensation, and gastroparesis. DN may affect the peripheral motor and sensory nerves in addition to the autonomic nervous system (1-3). Treatment strategies for patients with DN have generally concentrated on pain relief, without addressing the underlying pathophysiology of the disease (4). Anecdotal reports from patients treated with pulsatile insulin for other complications suggest that this treatment may show efficacy in patients with DN. This study is designed to compare patients with DN who receive pulsatile insulin with a control group.
Pulses of IV insulin encourages the glucose metabolism in diabetics to normalize in multiple organs, especially muscle, retina, liver, kidney and nerve endings. The process fundamentally requires the administration of high dose insulin pulses similar to those found in non diabetic humans by their pancreas into the surrounding portal circulation. Oral carbohydrates are given simultaneously to augment the process and prevent hypoglycemia. The process is monitored by frequent measuring of glucose levels and respiratory quotients (RQ). RQ is measured by a metabolic cart which determines the ratio VCO2/ VO2. This ratio is specific for the fuel used at any one time by the body. The glucose levels are monitored to keep glucose levels appropriate and the RQ determines the need to readjust the infusion protocol in each patient for subsequent insulin infusion sessions. The insulin pulses are delivered over 1-hour periods with a 1-hour rest period between each session. Three treatments are given during each treatment day.
The respiratory quotient (RQ) is a measurement of CO2 exhaled and O2 inhaled and is proportionate to the fuel sources being used by the body, primarily the liver over short periods of time. The higher the RQ, the more glucose and less alternative fuel sources are being utilized. Following the RQ change helps determine the effectiveness of physiological insulin administration in increasing anabolic functions in diabetic individuals. By improving the body's glucose metabolism and thereby causing beneficial effects of anabolic factors, the possibility of serious complications can be decreased. In addition the use of oral carbohydrate at the same time along with the physiologic insulin administration stimulates the appropriate gut hormones which augment this effect, a response which cannot be duplicated with intravenous glucose. The purpose of our studies is to determine whether the physiologic administration of insulin along with the augmenting effect of oral carbohydrates will normalize metabolism in diabetic patients and correlate with an improvement in their manifestations of diabetic neuropathy.
The RQ is determined by the use of a metabolic cart. Individuals breathe into a mask for 3-5 minutes after a rest period of 30 or more minutes. The ratio of exhaled volume of CO2 to the inhaled volume of O2 is determined as the RQ. The physiologic range is 0.7 to1.3. Individuals using fat as a primary fuel have a ratio of 0.7, protein or mixed fuels is 0.8-0.9 and carbohydrate is 0.9-1.0. Those taking excessive calories will have RQ's higher than 1.05.
- Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH, Vascular Risk factors and Diabetic Neuropathy N Engl J Med 352:341-50, 2005.
- Neuropathy Trust, Diabetic Neuropathy:Prevalence, www.neurocentre.com.
- Potter PJ, Maryniak O, Yamorski R, Jones IC, Incidence of Peripheral Neuropathy in the Contralateral Limb of Persons with Unilateral Amputation due to Diabetes, Journal of Rehabilitation Research and Development 35:335-39, 1998.
- Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengan , Duloxetine versus Placebo in Patients with Painful Diabetic Neuropathy, Pain 116:109-18, 2005.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Florida
-
Boca Raton, Florida, United States, 33431
- Florida Atlantic University Center for Complex Systems and Brain Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The researchers will include up to 500 patients both male and female between the ages of 20 and 90 diagnosed with type 1 or type 2 diabetes mellitus.
- All patients were diagnosed by their endocrinologists as having diabetic neuropathy
- All patients had failed conventional treatment for diabetic neuropathy
- Taking oral agents and/or insulin for diabetic control
- Under an Endocrinologists supervision for their diabetes management. Endocrinologist must assess and approve patient for participation in this study
- Ability to swallow without difficulty
- Ability to commit to the weekly time requirements associated with the study
Exclusion Criteria:
- Other causes of complications not related to diabetes
- Lack of intravenous access
- Pregnancy
- Alcohol abuse, drug addiction or the use of illegal drugs
- Positive HIV
- Inability to breathe into machine for respiratory quotients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2
Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
|
Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis.
Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
Other Names:
|
Placebo Comparator: 1
Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
|
Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measure the stabilization or reduction of the decline of diabetic neuropathy by pt questionnaires and diagnostic tests
Time Frame: Measure the stabilization and reduction of complications associated with diabetic neuropathy
|
Measure the stabilization and reduction of complications associated with diabetic neuropathy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Betty Tuller, PhD, Florida Atlantic University
Publications and helpful links
General Publications
- Gill G, Moulik P. Mortality and diabetic neuropathy. Diabet Med. 2005 Sep;22(9):1289. doi: 10.1111/j.1464-5491.2005.01729.x. No abstract available.
- Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi: 10.1016/j.clineuro.2005.08.003. Epub 2005 Sep 16.
- Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005 Jan 27;352(4):341-50. doi: 10.1056/NEJMoa032782.
- Potter PJ, Maryniak O, Yaworski R, Jones IC. Incidence of peripheral neuropathy in the contralateral limb of persons with unilateral amputation due to diabetes. J Rehabil Res Dev. 1998 Jul;35(3):335-9.
- Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 Jul;116(1-2):109-18. doi: 10.1016/j.pain.2005.03.029.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H09-66 NEU1
- MH42900 and MH01386 (NIMH)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, With Complications
-
Peking Union Medical College HospitalChinese Academy of Sciences; The First Affiliated Hospital of Zhengzhou University and other collaboratorsNot yet recruitingEfficacy and Safety of Bifidobacterium Quadruple Live Tablets in Patients With T2DM and ConstipationType 2 Diabetes Mellitus With ComplicationChina
-
Heidelberg Engineering GmbHCompletedNormal Eyes of Subjects Without Diabetes Mellitus | Subjects With Diabetes Mellitus Type 2 Without Coexisting DPN | Subjects With Diabetes Mellitus Type 2 With Coexisting Early to Moderate DPN
-
McGill University Health Centre/Research Institute...The Lawson FoundationCompletedGestational Diabetes Mellitus With Baby DeliveredCanada
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingType 2 Diabetes Mellitus With Complication
-
Florida Atlantic UniversityAdvanced Diabetes Treatment Centers; Global InfusionsTerminatedDiabetes Mellitus, With ComplicationsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingType 2 Diabetes Mellitus With ComplicationChina
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Sheba Medical CenterUnknownType I Diabetes Mellitus With Ulcer | Type II Diabetes Mellitus With UlcerIsrael
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR)CompletedGestational Diabetes Mellitus With Baby DeliveredCanada
Clinical Trials on Effect of Pulsatile IV Insulin on diabetic neuropathy
-
Florida Atlantic UniversityAdvanced Diabetes Treatment CentersTerminatedDiabetes MellitusUnited States
-
Florida Atlantic UniversityAdvanced Diabetes Treatment Centers; Global InfusionsTerminatedDiabetes Mellitus, With ComplicationsUnited States
-
Florida Atlantic UniversityAdvanced Diabetes Treatment CentersTerminatedDiabetes MellitusUnited States
-
Florida Atlantic UniversityAdvanced Diabetes Treatment CentersTerminatedDiabetes MellitusUnited States
-
Kahramanmaras Sutcu Imam UniversityCompletedDiabetes Mellitus | Diabetic Retinopathy | HormonesTurkey
-
Gianna WilkieCompletedType 1 Diabetes | Pregnancy, High RiskUnited States
-
Florida Atlantic UniversityAdvanced Diabetes Treatment Centers; Global InfusionsWithdrawnDiabetic NeuropathyUnited States
-
Florida Atlantic UniversityAdvanced Diabetes Treatment CentersWithdrawnDiabetes Mellitus, With ComplicationsUnited States
-
University of JordanUnknownStudying the Effect of Mediterranean Diet on Insulin Resistance Among Obese Children and AdolescentsInsulin Resistance | Obesity, ChildhoodJordan